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Introduction
============

The identification of molecules associated with specific genomic regions of interest is required to understand the mechanisms of regulation of genomic functions such as transcription and epigenetic regulation. Although several techniques have been developed for biochemical analysis of specific genomic regions^1-7^, they are not used widely at this stage because of their intrinsic problems such as limited application (*e.g.,* only for high-copy number loci or loci with repeats) and too much time and efforts required.

In order to perform biochemical analysis of specific genomic regions easily, we have developed two locus-specific chromatin immunoprecipitation (ChIP) technologies, namely insertional ChIP (iChIP)^8-13^ and engineered DNA-binding molecule-mediated ChIP (enChIP)^14-17^. In iChIP, a locus of interest is tagged by inserting recognition sequences of an exogenous DNA-binding protein such as LexA. The locus is then isolated by affinity purification using the tagged DNA-binding protein. In enChIP, engineered DNA-binding molecules, such as zinc-finger proteins, transcription activator-like (TAL) proteins, and clustered regularly interspaced short palindromic repeats (CRISPR) complexes, are used to tag a locus of interest (**Figure 1**). Subsequently, the genomic region is isolated by affinity purification of the tagged DNA-binding molecules.

One of the advantages of enChIP over iChIP is that insertion of recognition sequences of an exogenous DNA-binding protein is not necessary. Targeting of loci using CRISPR complexes consisting of a catalytically inactive form of Cas9 (dCas9) and a guide RNA (gRNA) is much easier than targeting of these regions by iChIP or enChIP using TAL and zinc-finger proteins. Here, we describe a step-by-step protocol for enChIP combined with mass spectrometry and RNA sequencing (RNA-Seq) to identify locus-associated proteins and RNAs, respectively.

Protocol
========

1. Design of Engineered DNA-binding Molecules Recognizing the Target Locus
--------------------------------------------------------------------------

1.  For enChIP using CRISPR complexes, use the CRISPRdirect web tool (http://crispr.dbcls.jp) to identify candidate gRNA target sequences in the genomic region of interest described as previously^18^. This web tool returns 23 bp genomic sites of the form 5\'-N~20~NGG-3\' within the target region.

2.  Synthesize a gBlock including the U6 promoter sequence and the sequence of 5\'-N~20~ in 5\'-N~20~NGG-3\' using commercial services (see **Figure 2**)^19,20^. For subcloning purposes, include appropriate restriction enzyme sites outside of the gBlock.

3.  Insert the gBlock into an appropriate vector as previously described^16^. Several retroviral vectors for gBlocks are available (see **Materials**).

4.  For enChIP using TAL proteins, design TAL proteins recognizing the target loci. Generate plasmids encoding TAL proteins using commercial services. Generate expression vectors containing the TAL proteins fused with one or more tags such as 3×FLAG as previously described^15^.

2. Establishment of Cells for the enChIP Analysis
-------------------------------------------------

1.  Express 3×FLAG-dCas9 and the gRNA (CRISPR-based procedure) or 3×FLAG-TAL (TAL protein-based procedure) in the cells to be analyzed as described previously^14-17^. Use transient transfection if the transfection efficiency is high. An expression vector containing 3×FLAG-dCas9 and the CMV promoter is available (see **Materials**).Consider establishing stable transformants using conventional methods if the transient transfection efficiency is low. In addition to the aforementioned retroviral vectors for gBlock, retroviral vectors of 3×FLAG-dCas9 are available (see **Materials**).

2.  Confirm the expression of the 3xFLAG-dCas9 or 3xFLAG-TAL protein in the transfected cells by immunoblot analysis using an anti-FLAG antibody (Ab) as described previously^14-17^. Note: Expression of these tagged proteins can also be confirmed by intracellular staining with anti-FLAG-FITC and a subsequent FACS analysis. A protocol for intracellular staining can be downloaded from our homepage (http://www.biken.osaka-u.ac.jp/lab/microimm/fujii/iChIP_protocols/english.html).

3.  Confirm expression of the gRNA by standard RT-PCR technique.

4.  For quantitative identification of proteins interacting with the genomic region of interest, consider use of a stable isotope labeling by amino acids in cell culture (SILAC) analysis combined with enChIP (enChIP-SILAC). Note: Media for the SILAC analysis can be purchased from commercial vendors. SILAC is powerful in detecting specific interactions. Culture cells in SILAC heavy medium. Prepare cells cultured in SILAC light medium as a negative control. Use at least 5 × 10^7^ cells for each SILAC medium (heavy or light). For efficient labeling, add both L-Lysine-2HCl, ^13^C~6~ and L-Arginine-HCl, ^13^C~6~, ^15^N~4~ in the SILAC Heavy media. Note: At least five cell divisions are necessary to label proteins. For example, culture human fibrosarcoma HT1080 cells stably expressing 3xFLAG-dCas9 and a gRNA at 37 °C and 5% CO~2~ in DMEM media for SILAC and dialyzed fetal bovine serum with Lysine-2HCl plus L-Arginine-HCl (Light medium) or ^13^C~6~ L-Lysine-2HCl plus ^13^C~6~^15^N~4~ L-Arginine-HCl (Heavy medium) (see **Materials**)^16^. Add 50 mg of light or heavy L-Lysine-2HCl and L-Arginine-HCl in 500 ml of medium.Trypsinize and replate cells before they become confluent so that cells maintain exponential growth.

3. Crosslinking of Cells with Formaldehyde
------------------------------------------

1.  For cells in suspension culture, transfer 2 × 10^7^ cells expressing 3xFLAG-TAL proteins or 3xFLAG-dCas9 plus gRNA and suspend in 30 ml of regular culture medium in a 50 ml centrifuge tube. When more cells are used, increase the volumes and amounts of reagents proportionally. For SILAC experiments, mix the cells cultured in heavy medium or light medium (5 x 10^7^ cells each) and divide the total of 1 x 10^8^ cells into 5 tubes containing 2 x 10^7^ cells.

2.  Add 810 µl of 37% formaldehyde to 30 ml of the cell suspension (final concentration 1%) and incubate at 37 °C for 5 min. For adherent cells, directly fix cells in culture dishes by adding 810 µl of 37% formaldehyde to 30 ml of culture medium.

3.  Stop the crosslinking by adding 3.1 ml of 1.25 M glycine solution (final concentration 127 mM), and incubate at RT for 10 min.

4.  Collect cells by centrifugation (300 × g for 5 min at 4 °C). Carefully discard the supernatant including formaldehyde and store it in an appropriate waste bottle. For adherent cells, detach cells with a cell scraper and harvest in a 50 ml tube, and collect cells as described in this step.For SILAC experiments, mix the detached cells cultured in heavy medium or light medium (5 x 10^7^ cell each), divide the total of 1 x 10^8^ cells into 5 tubes containing 2 x 10^7^ cells, and collect cells as described in this step.

5.  Wash the cell pellet with 30 ml of PBS twice per tube. Carefully discard the supernatant including formaldehyde and store it in an appropriate waste bottle.Handle the formaldehyde waste according to chemical safety guidelines. The fixed cells can be frozen and stored at -80 °C.

4. Preparation of Chromatin (per 2 x 10^7^ cells)
-------------------------------------------------

1.  Suspend the fixed cells in 10 ml of cell lysis buffer (10 mM Tris (pH 8.0), 1 mM EDTA, 0.5% IGEPAL CA-630, and 1× protease inhibitors) and incubate on ice for 10 min.

2.  Centrifuge the sample (830 × g at 4 °C for 8 min) and discard the supernatant carefully.

3.  Suspend the pellet in 10 ml of nuclear lysis buffer (10 mM Tris (pH 8.0), 1 mM EDTA, 0.5 M NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.5% lauroylsarcosine, and 1x protease inhibitors). Incubate on ice for 10 min and vortex every 2-3 min.

4.  Centrifuge the sample (830 ×g at 4 °C for 8 min) and discard the supernatant carefully*.*

5.  Wash the pellet in 10 ml of PBS. The pellet (chromatin fraction) can be stored at -80 °C after immediate freezing in liquid nitrogen.

5. Sonication of Chromatin (per 2 x 10^7^ cells)
------------------------------------------------

1.  Suspend the chromatin fraction in 800 µl of modified lysis buffer 3 (10 mM Tris (pH 8.0), 1 mM EDTA, 150 mM NaCl, 0.1% sodium deoxycholate, 0.1% SDS, and 1x protease inhibitors) and transfer into a 1.5 ml tube.

2.  Sonicate the chromatin using a sonicator (see Materials) and the following conditions: output: 3; duty: 100% (continuous); and time: free. Perform 10-18 cycles of sonication for 10 sec and cooling on ice for 20 sec. To avoid excessive heating, incubate the samples on ice for 2 min every 5-6 cycles. To avoid foaming, keep the position of the tip of the sonication probe 0.5 cm above the bottom of the tube.

3.  Centrifuge the sample at (16,000 × g at 4 °C for 10 min) and transfer the supernatant into a 1.5 ml tube. The sonicated chromatin can be stored at -80 °C after immediate freezing in liquid nitrogen.

6. Evaluation of Chromatin Fragmentation
----------------------------------------

1.  Mix 10 µl of the fragmented chromatin with 85 µl of distilled water.

2.  Add 4 µl of 5 M NaCl and incubate at 65 °C O/N.

3.  Add 1 µl of 10 mg/ml RNase A and incubate at 37 °C for 45 min.

4.  Add 2 µl of 0.5 M EDTA (pH 8.0), 4 µl of 1 M Tris (pH 6.8), and 1 µl of 20 mg/ml Proteinase K, and then incubate at 45 °C for 1.5 hr.

5.  Separate 10 µl of the sample by electrophoresis in a 1% agarose gel that does not contain staining dyes such as SYBR Green.

6.  Stain the gel to evaluate the distribution of the lengths of the fragmented chromatin. Conditions that generate an average length of 0.5-2 kbp (range of 0.2-4 kbp) are recommended.

7.  Purify DNA from the remaining samples by phenol-chloroform extraction or by using a DNA extraction kit (see **Materials**). The purified DNA can be used as input DNA to estimate the yields of enChIP analyses (see 8.11).

7. Preparation of Dynabeads Conjugated with Antibodies (per 2 x 10^7^ cells)
----------------------------------------------------------------------------

1.  Prepare two 1.5 ml tubes, one for pre-clearing using normal mouse IgG and the other for incubation with the anti-FLAG Ab. Add 150 µl of Protein G-conjugated magnetic beads (see Materials) to each tube.

2.  Place the tubes on a magnet stand and wait for 3 min. Discard the supernatant by pipetting.

3.  Suspend the beads in 1 ml of PBS containing 0.01% Tween-20 (PBS-T). Place the tubes on a magnetic stand and wait for 2 min. Discard the supernatant by pipetting, and then repeat the step.

4.  Suspend the beads in 1 ml of PBS-T containing 0.1% BSA.

5.  Add 15 µg of normal mouse IgG or anti-FLAG Ab and rotate at 4 °C O/N.

6.  Spin down briefly, then place the tubes on a magnet stand and wait for 3 min. Discard the supernatant by pipetting.

7.  Suspend the beads in 1 ml of PBS-T. Invert the sample several times and spin down briefly. Place the tubes on a magnet stand and wait for 3 min, then discard the supernatant by pipetting. Repeat the wash two more times with PBS-T (total of three wash steps).

8. Chromatin Immunoprecipitation (per 2 x 10^7^ cells)
------------------------------------------------------

1.  Mix the fragmented chromatin prepared in 5.3) (approximately 800 µl) with one-fifth of the volume (approximately 200 µl) of modified lysis buffer 3 containing 5% Triton X-100 (final concentration of 1% Triton X-100 ).

2.  Add the chromatin solution to the tube in which Protein G-conjugated magnetic beads conjugated with normal mouse IgG were prepared. Rotate at 4 °C for 1 hr.

3.  Place the tube on a magnet stand and wait for 3 min.

4.  Transfer the supernatant into the tube in which Protein G-conjugated magnetic beads conjugated with anti-FLAG Ab were prepared. Rotate at 4 °C O/N.

5.  Place the tube on a magnet stand and wait for 3 min. Discard the supernatant by pipetting.

6.  Suspend the beads in 1 ml of low salt buffer (20 mM Tris (pH 8.0), 2 mM EDTA, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, and 1x protease inhibitors) and rotate at 4 °C for 5 min. Place the tube on a magnet stand and wait for 3 min. Discard the supernatant by pipetting and repeat the wash step.

7.  Wash the beads with high salt buffer (20 mM Tris (pH 8.0), 2 mM EDTA, 500 mM NaCl, 1% Triton X-100, 0.1% SDS, and 1x protease inhibitors) twice.

8.  Wash the beads with LiCl buffer (10 mM Tris (pH 8.0), 1 mM EDTA, 250 mM LiCl, 0.5% IGEPAL CA-630, 0.5% sodium deoxycholate, and 1x protease inhibitors) twice.

9.  Wash the beads with TBS-IGEPAL CA-630 (50 mM Tris (pH 7.5), 150 mM NaCl, 0.1% IGEPAL CA-630, and 1x protease inhibitors) once.

10. Suspend the beads in 200 µl of elution buffer (50 mM Tris (pH 7.5), 150 mM NaCl, 0.1% IGEPAL CA-630, 1x protease inhibitors, and 500 µg/ml 3×FLAG peptide) and incubate at 37 °C for 20 min. Place the tube on a magnet stand and wait for 3 min. Transfer the supernatant into a new 1.5 ml tube and repeat the elution step.

11. Purify DNA from small portion (*e.g., *5%) of the eluate by phenol-chloroform extraction or by using a DNA extraction kit (see Materials). The purified DNA can be used for PCR with specific primer sets to estimate the yields of enChIP analyses by comparing with input DNA prepared in Step 6.7 as described previously^14,16^.

9. SDS-PAGE, Staining, and Mass Spectrometric Analysis
------------------------------------------------------

1.  Mix the eluate (400 µl) with 1 ml of 2-propanol, 50 µl of 3M sodium acetate (pH 5.2), and 5 µl of 20 mg/ml glycogen. Precipitate the chromatin at -20 °C O/N.

2.  Centrifuge the sample (16,000 × g at 4 °C for 30 min) and discard the supernatant. Rinse the pellet with 1 ml of 70% ethanol and centrifuge again (16,000 × g at 4 °C for 10 min). Discard the supernatant completely by pipetting.

3.  Suspend the pellet in 40 µl of 2x sample buffer (125 mM Tris (pH 6.8), 10% 2-mercaptoethanol, 4% SDS, 10% sucrose, and 0.004% bromophenol blue). Vortex for 5 min to dissolve the pellet completely, and then incubate at 100 °C for 30 min to denature the proteins and reverse the crosslinking.

4.  For SDS-PAGE, run 40 µl of the sample on the gel until the dye reaches 1 cm below the well. Note: We usually use 4-20% gradient gels, but other % gels can be used.

5.  Stain the gel with Coomassie Brilliant Blue or silver stain.

6.  Cut the gel into five pieces (2 mm height).

7.  Perform in gel digestion and mass spectrometric analysis as described previously^13-16^.

8.  For SILAC experiments with 5 x 10^7^ cells each (total of 1 x 10^8^ cells), suspend pellet from the initial five tubes in 40 µl of 2x sample buffer (it is not necessary to scale up).

10. Purification of RNA and RNA-Seq Analysis
--------------------------------------------

1.  To purify the RNA after enChIP, add 5 U/ml of RNase Inhibitor (see Materials) to all of the buffer solutions, except modified lysis buffer 3 and the elution buffer, to which add 40 U/ml of RNase Inhibitor.

2.  Mix the eluate (400 µl) with 16 µl of 5 M NaCl and incubate at 65 °C for 2 hr.

3.  Add 1 ml of acid-guanidinium-phenol-based reagent (see Materials) to the sample. Vortex for 15 sec and then incubate at RT for 5-15 min. Centrifuge the sample for 15 min at 12,000 × g and RT.

4.  Transfer the supernatant to a new 1.5 ml tube and add 5 µl of p-bromoanisole. Vortex for 15 sec and then incubate at RT for 3-5 min. Centrifuge the sample for 10 min at 12,000 × g and RT*.*

5.  Transfer the supernatant (approximately 1 ml) into a new 2 ml tube and add 1 ml of 2-propanol. Invert the tube and incubate at RT for 10 min. Load the mixture onto a column in an RNA purification kit (see **Materials**). Centrifuge the column for 1 min at 12,000 ×g and RT.

6.  Wash the column with 400 µl of RNA Wash Buffer in an RNA purification kit (see Materials).

7.  Add 80 µl of DNase I cocktail (mixture of 5 µl of DNase I (1 U/µl), 8 µl of 10× DNase I Reaction Buffer, 3 µl of DNase/RNase-free water, and 64 µl of RNA Wash Buffer in an RNA purification kit (see Materials)) to the column. Incubate the sample at 37 °C for 15 min and then centrifuge  for 30 sec at 12,000 × g and RT.

8.  Wash the column with 400 µl of RNA PreWash Buffer in an RNA purification kit (see Materials) twice.

9.  Elute the RNA with 50 µl of DNase/RNase-free water. The eluted RNA can be used for RNA sequencing.

Representative Results
======================

Overall, 1-30% of target genomic regions can be purified using enChIP. **Figure 3** includes representative data showing the yields of enChIP analyses targeting telomeres and the promoter of the interferon (IFN) regulatory factor-1 (*IRF-1*) gene. As examples of typical results, **Table 1** lists the proteins associated with the *IRF-1* promoter in an IFNγ-specific manner identified by enChIP-SILAC, **Table 2**lists the telomere-binding proteins identified by enChIP combined with mass spectrometry (enChIP-MS), and **Table 3** lists the RNAs associated with telomeres identified by enChIP-RNA-Seq.

**Figure 1.Overview of enChIP**. enChIP using CRISPR (**A, B**) and TAL (**C, D, E**) is shown. A locus of interest is tagged with engineered DNA-binding molecules such as a TAL protein or the CRISPR system consisting of a catalytically inactive form of Cas9 (dCas) and guide RNA (gRNA). The molecular interactions are fixed with formaldehyde or other crosslinkers, if necessary. Subsequently, fixed chromatin is fragmented by sonication or enzymatic digestion. The tagged genomic regions are purified by affinity purification. Finally, crosslinking is reversed, and interacting molecules (genomic regions, RNAs, and proteins) are identified using next generation sequencing and mass spectrometry. [Please click here to view a larger version of this figure.](https://www.jove.com/files/ftp_upload/53478/53478fig1large.jpg)

**Figure 2. Sequence of gBlock.** The U6 promoter (in black), the G nucleotide before the guide sequence (in blue), the guide sequence (gRNA spacer) (in red), the scaffold sequence (in green), and the terminator sequence (in orange) are shown.

**Figure 3. Yields of representative enChIP analyses**. (**A**) Percentage inputs for the target *IRF-1* locus and the non-target *Sox2* locus. (**B**) Percentage inputs for the target telomeres and non-target γ-satellites. The figures have been adapted and modified from previous publications^15,16^.

  ------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------
  **Categories**                                   **Proteins**
  Transcription                                    DDX1, PARP1, CKAP4, Pescadillo homolog, PURβ, activated RNA polymerase II transcriptional activator p15, BTF3, Myb-binding protein 1A
  Histone  deacetylation, corepressor components   RBBP4, PA2G4, TBL3
  Acetyltransferase                                Protein arginine N-methyltransferase 1
  DNA topoisomerase                                DNA topoisomerase 2α
  Histones                                         Histone H2A.Z, histone H3.2
  ------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------

**Table 1:Examples of proteins associated with the human *IRF-1* promoter region in an IFNγ-specific manner identified by enChIP-SILAC.** The table has been adapted from a previous publication^16^.

  --------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------
  **Categories**                                                                                **Proteins**
  Mammalian telomere-binding proteins                                                           PML, RPA, CDK1, PARP1, PCBP1
  Telomere-binding proteins in yeast or other organisms                                         IMP4
  Proteins interacting with telomere-binding proteins \[associated telomere-binding protein\]   DNA polymerase α (POLA1) \[Cdc13p\], ARMC6 \[TRF2\], CTBP1 \[FoxP2-POT1\], exportin-5 \[TERT\], GNL3L \[TRF1\], exportin-1 \[TERT\], 14-3-3 \[TERT\]
  Proteins localizing to heterochromatin                                                        BEND3
  Proteins regulating epigenetic marks                                                          KDM5C
  Proteins whose mutations affect telomere function                                             DNA polymerase α (POLA1), HAT1, Nup133, CDK7, DPOE1, PRDX1, TYSY, glutamate-cysteine ligase, glutaredoxin, SMRC1
  --------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------

**Table 2:Examples of proteins associated with mouse telomeres identified by enChIP-MS.** The table has been adapted from a previous publication^15^.

  ----------------------- -----------------------------------------
  **Categories**          **RNAs**
  Telomerase components   *Terc, Rmrp*
  Telomeric RNAs          TERRAs
  scaRNAs                 *Scarna6, Scarna10, Scarna13, Scarna2*
  H/ACA snoRNAs           *Snora23, Snora74a, Snora73b, Snora73a*
  C/D snoRNAs             *Snord17, Snord15a, Snord118*
  lncRNA                  *Neat1*
  ----------------------- -----------------------------------------

**Table 3:Examples of RNAs associated with mouse telomeres identified by enChIP-RNA-Seq.** The table has been adapted from a previous publication^17^.

Discussion
==========

Here, we describe the purification of specific genomic regions using engineered DNA-binding molecules such as the CRISPR system and TAL proteins, and the identification of proteins and RNAs bound to these genomic regions. Binding of engineered DNA-binding molecules to the genome may affect chromatin structure, including nucleosome positioning, and may abrogate genomic functions, as described in CRISPR interference experiments^21^. To avoid these potential aberrant effects, we propose specific guidelines for choosing target genomic regions. First, to avoid potential inhibition of the recruitment of RNA polymerases and transcription factors, as well as disruption of nucleosome positioning around the transcription start site, the target regions for analyses of promoter regions should be several hundred base pairs upstream of (5\' to) the transcription start site. By contrast, when analyzing genomic regions with distinct boundaries, such as enhancers and silencers, genomic regions that are directly juxtaposed to these regions can be targeted because it is less likely that the binding of engineered DNA-binding molecules will affect their functions. Furthermore, it is best to avoid using target regions that are conserved among different species, because important DNA-binding molecules often bind to evolutionarily conserved regions and inhibition of their binding might disrupt the functions of the target genomic regions. In this regard, it is always necessary to check that the function of the target genomic region is maintained in the established cells used for enChIP analyses. Because multiple gRNAs can be tested easily and it is tedious and expensive to generate multiple versions of TAL or zinc-finger proteins recognizing different target genomic regions, enChIP using CRISPR is more advantageous than enChIP using other proteins.

It has been shown that dCas9 binds to off-target sites although affinity to those sites might be weaker than that to the target sites^22-25^. There are several ways to manage contamination of molecules bound to those off-target sites. First, the use of several, at least two, different gRNAs would be recommended. Those molecules commonly observed in enChIP using distinct gRNAs would be true positives. Second, comparison of different conditions for enChIP would be effective in cancelling contamination of non-specific molecules and molecules bound to off-target sites. Examples of those comparison sets would be (i) stimulation (-) and (+), or (ii) different cell types such as T cells vs. B cells. Finally, quantitative analysis of binding of candidate molecules should be performed to confirm their specific binding to the target sites. It is preferable to prepare cells expressing only dCas9 but not gRNA as a negative control.

Using enChIP analyses, we were able to successfully identify a number of known and novel molecules interacting with specific genomic regions (**Tables 1-3**)^14-17^. However, this technique failed to detect some other known proteins interacting with these regions. For example, STAT1 reportedly associates with the *IRF-1* promoter upon IFNγ stimulation^8^, but our enChIP-SILAC analysis did not detect STAT1 as a protein induced to interact with this genomic region^16^. In addition, in the enChIP-MS analysis of telomeres, we did not detect shelterin proteins consisting of TRF-1 and TRF-2^15^, which have been shown to interact with telomeres^26^. There are a few potential reasons for these discrepancies. First, the stoichiometry of binding of Stat1 to the *IRF-1* promoter might be very low. It is reasonable that enChIP-MS, including enChIP-SILAC, detects proteins that are more abundantly associated with target genomic regions; hence, the analysis of more cells might be necessary to detect these proteins. Increases in the sensitivities of MS instruments would also contribute to the efficient detection of proteins with low stoichiometric binding. Second, some proteins, possibly including Stat1 and shelterins, might be difficult targets for MS analyses. Third, in our analysis of telomere-binding proteins^15^, the 3×FLAG-TAL proteins recognizing telomeres (3×FN-Tel-TAL) might have blocked the binding of shelterins to telomeres in a competitive fashion.

In contrast to the relative difficulty of detecting transcription factors binding to specific genomic regions using enChIP, we successfully identified epigenetic regulators such as histone modification enzymes using enChIP analyses. The success of this technique may be due to the fact that epigenetic regulators bind to a broad range of genomic regions; hence, more proteins per genomic region are available for MS. Because epigenetic regulators are increasingly recognized as important targets for drugs against intractable diseases such as cancer, enChIP would be a useful tool for the identification of epigenetic drug targets.
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